Literature DB >> 19384323

Dialysis: preventing hypophosphatemia during pediatric CRRT.

Zaccaria Ricci1, Claudio Ronco.   

Abstract

A recent report showed that hypophosphatemia is common in children undergoing continuous renal replacement therapy, and that adding phosphate to the replacement and dialysate solutions significantly reduced the incidence of this complication. Should such supplementation be routinely performed?

Entities:  

Mesh:

Year:  2009        PMID: 19384323     DOI: 10.1038/nrneph.2009.49

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  6 in total

1.  Impact of continuous veno-venous hemofiltration on acid-base balance.

Authors:  J Rocktäschel; H Morimatsu; S Uchino; C Ronco; R Bellomo
Journal:  Int J Artif Organs       Date:  2003-01       Impact factor: 1.595

Review 2.  Technical considerations for renal replacement therapy in children.

Authors:  Timothy E Bunchman; Patrick D Brophy; Stuart L Goldstein
Journal:  Semin Nephrol       Date:  2008-09       Impact factor: 5.299

3.  Primum non nocere, safety of continuous renal replacement therapy.

Authors:  Heleen M Oudemans-van Straaten
Journal:  Curr Opin Crit Care       Date:  2007-12       Impact factor: 3.687

4.  Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy.

Authors:  Stéphan Troyanov; David Geadah; Marc Ghannoum; Jean Cardinal; Martine Leblanc
Journal:  Intensive Care Med       Date:  2004-05-20       Impact factor: 17.440

5.  Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children.

Authors:  Maria José Santiago; Jesús López-Herce; Javier Urbano; Jose María Bellón; Jimena del Castillo; Angel Carrillo
Journal:  Kidney Int       Date:  2008-11-12       Impact factor: 10.612

6.  Circuit lifespan during continuous renal replacement therapy: children and adults are not equal.

Authors:  Zaccaria Ricci; Isabella Guzzo; Stefano Picca; Sergio Picardo
Journal:  Crit Care       Date:  2008-09-16       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.